LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE
Pre-Launchlamivudine; tenofovir disoproxil fumarate; nevirapine
NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 2w ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
This is a fixed-dose combination tablet containing lamivudine, tenofovir disoproxil fumarate, and nevirapine—three antiretroviral agents used to treat HIV-1 infection. The combination targets HIV replication through complementary mechanisms: lamivudine and tenofovir are nucleos(t)ide reverse transcriptase inhibitors, while nevirapine is a non-nucleoside reverse transcriptase inhibitor. This oral tablet formulation simplifies dosing for HIV patients by combining three active ingredients in a single dose.
Pre-Launch
As a pre-launch product from Aurobindo Pharma, this represents early-stage commercial opportunity with teams focused on regulatory approval, launch strategy, and market positioning in the competitive HIV therapeutic space.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Joining Aurobindo on this pre-launch product offers exposure to regulatory approval, go-to-market strategy, and emerging-market commercialization in a competitive, high-volume therapeutic category. Career visibility is limited until approval and launch, but success can demonstrate expertise in complex fixed-dose combination registration and global HIV market dynamics.
Regulatory Affairs Specialist
Worked on LAMIVUDINE; TENOFOVIR DISOPROXIL FUMARATE; NEVIRAPINE at Aurobindo Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.